Vine VC

vine.vc

Vine invests across three interconnected domains: psychedelics (novel approaches to conscious health & wellness), neurotechnology (brain mapping, neuromodulation, BCIs), and longevity (therapies targeting hallmarks of aging). They target early-stage companies seeking to advance novel modalities for mental health and wellbeing, with particular interest in entrepreneurs and builders working on projects with significant impact potential.

Check Size

Not specified

Stages

Pre Seed, Seed, Series A, Growth

Focus Areas

Healthtech, Biotech, Medtech

Is Vine VC right for your startup?

Upload your pitch deck and get an AI-powered match score in minutes. See exactly how well you fit their investment criteria.

See If You're a Match

Investment Thesis

Vine Ventures was founded to address the global mental health crisis by driving the emergence of innovative solutions for mental health and wellbeing. The firm is rethinking venture capital for a novel approach to health and wellness, with a core belief that ‘the two most pressing problems facing humanity are mental health and aging.’ They emphasize investing in ‘constructive not extractive capital’ and seek to create an ethical industry rather than extractive business models. The firm operates smaller funds with niche focus where managers can comprehensively survey their markets, identify outlier founders, and provide contextually valuable support.

What Sets Them Apart

Reciprocity pledge: 50% of GP profits are donated back to the mental health community, scaling from 20% at 2x DPI to 50% at 5x DPI
Deep market expertise across three interconnected domains (psychedelics, neurotechnology, longevity) with tracking of ~1,000 psychedelic companies and 300+ longevity companies
Preference for 'cash flow positive, default alive positions' alongside high-conviction bets, favoring businesses with positive unit economics
Focus on 'high-integrity teams' and ethical approaches to avoid dystopian futures of expensive, sterile treatments with no community connection
Portfolio includes representative companies addressing the middle of the value chain where more value accrues than venture capital deployed